Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931283 | 0.84 | RPA1 (0.47) | CNR1CNR2ALDH1A1OPRM1 | |
| SCHEMBL1432762 | 0.82 | KDM4E (0.53) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL4927334 | 0.81 | MARS1 (0.43) | CNR1CNR2ALDH1A1OPRM1 | |
| SCHEMBL923749 | 0.75 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL679341 | 0.74 | KMT2A (0.37) | KDM4EMEN1MAPTKMT2AFAAH | |
| SCHEMBL6314587 | 0.74 | KMT2A (0.56) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL1432626 | 0.73 | KDM4E (0.52) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL1431800 | 0.72 | LMNA (0.46) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL4931540 | 0.72 | CNR1 (0.54) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL4932883 | 0.72 | CNR1 (0.54) | KDM4EMEN1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | CNR2, CNR1, OPRL1 | KDM4E 2084/4885MEN1 4398/4885MAPT 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.